AU2006200809B2 - Methods of treating cancer - Google Patents
Methods of treating cancer Download PDFInfo
- Publication number
- AU2006200809B2 AU2006200809B2 AU2006200809A AU2006200809A AU2006200809B2 AU 2006200809 B2 AU2006200809 B2 AU 2006200809B2 AU 2006200809 A AU2006200809 A AU 2006200809A AU 2006200809 A AU2006200809 A AU 2006200809A AU 2006200809 B2 AU2006200809 B2 AU 2006200809B2
- Authority
- AU
- Australia
- Prior art keywords
- hydroxy
- methyl
- deazaadenin
- pyrrolidine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 title claims abstract description 58
- 201000011510 cancer Diseases 0.000 title claims abstract description 43
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 24
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 20
- 201000010536 head and neck cancer Diseases 0.000 claims abstract description 14
- 208000014829 head and neck neoplasm Diseases 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 118
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 58
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 54
- -1 methoxy, amino Chemical group 0.000 claims description 52
- 150000002367 halogens Chemical class 0.000 claims description 44
- 229910052736 halogen Inorganic materials 0.000 claims description 42
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- PFTHSHCWMABFRB-UHFFFAOYSA-N 1-(benzylsulfanylmethyl)pyrrolidine Chemical compound C1CCCN1CSCC1=CC=CC=C1 PFTHSHCWMABFRB-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- MPRVSDYMZYXCEP-QMMMGPOBSA-N (3s)-3-amino-1-pyrrolidin-1-yl-5-sulfanylpentan-2-one Chemical compound SCC[C@H](N)C(=O)CN1CCCC1 MPRVSDYMZYXCEP-QMMMGPOBSA-N 0.000 claims description 2
- AZTBXUMWHCORIK-UHFFFAOYSA-N 1-(cycloheptylsulfanylmethyl)pyrrolidine Chemical compound C1CCCN1CSC1CCCCCC1 AZTBXUMWHCORIK-UHFFFAOYSA-N 0.000 claims description 2
- BAXMSZFRDMUXAM-UHFFFAOYSA-N 1-(cyclohexylmethylsulfanylmethyl)pyrrolidine Chemical compound C1CCCCC1CSCN1CCCC1 BAXMSZFRDMUXAM-UHFFFAOYSA-N 0.000 claims description 2
- AXGRVGKRLCRYGK-UHFFFAOYSA-N 1-(cyclopentylsulfanylmethyl)pyrrolidine Chemical compound C1CCCN1CSC1CCCC1 AXGRVGKRLCRYGK-UHFFFAOYSA-N 0.000 claims description 2
- SSPDKPRFFGTVRY-UHFFFAOYSA-N 1-(phenylsulfanylmethyl)pyrrolidine Chemical compound C1CCCN1CSC1=CC=CC=C1 SSPDKPRFFGTVRY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- DMKJHSANHDSZLV-UHFFFAOYSA-N 1-(cyclohexylsulfanylmethyl)pyrrolidine Chemical compound C1CCCN1CSC1CCCCC1 DMKJHSANHDSZLV-UHFFFAOYSA-N 0.000 claims 1
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 abstract description 41
- 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 abstract description 40
- 239000003112 inhibitor Substances 0.000 abstract description 38
- 101710136206 S-methyl-5'-thioadenosine phosphorylase Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 77
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 58
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 40
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 35
- 238000011282 treatment Methods 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 230000000694 effects Effects 0.000 description 21
- 239000005700 Putrescine Substances 0.000 description 20
- 229920000768 polyamine Polymers 0.000 description 19
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 17
- 210000002307 prostate Anatomy 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 229940125782 compound 2 Drugs 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 8
- 229930024421 Adenine Natural products 0.000 description 8
- 229960000643 adenine Drugs 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 101710185027 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase Proteins 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 150000002431 hydrogen Chemical group 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 101710081557 Aminodeoxyfutalosine nucleosidase Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 238000011789 NOD SCID mouse Methods 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000002224 dissection Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 150000003254 radicals Chemical group 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 3
- 229940063673 spermidine Drugs 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 210000002229 urogenital system Anatomy 0.000 description 3
- NTHMDFGHOCNNOE-ZJUUUORDSA-N (3r,4s)-1-[(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol Chemical compound C1[C@H](O)[C@@H](CSC)CN1CC1=CNC2=C(N)N=CN=C12 NTHMDFGHOCNNOE-ZJUUUORDSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 description 2
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- IQFWYNFDWRYSRA-OEQWSMLSSA-N S-(5-deoxy-beta-D-ribos-5-yl)-L-homocysteine Chemical compound OC(=O)[C@@H](N)CCSC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O IQFWYNFDWRYSRA-OEQWSMLSSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108010051753 Spermidine Synthase Proteins 0.000 description 2
- 102100030413 Spermidine synthase Human genes 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241001319955 Unda Species 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 210000001142 back Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000009643 clonogenic assay Methods 0.000 description 2
- 231100000096 clonogenic assay Toxicity 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- NFFPKRVXIPSSQR-BXXZVTAOSA-N (2r,3r,4r)-2,3,4,5-tetrahydroxypentanamide Chemical group NC(=O)[C@H](O)[C@H](O)[C@H](O)CO NFFPKRVXIPSSQR-BXXZVTAOSA-N 0.000 description 1
- GZPMMQGPHXEMSZ-UHFFFAOYSA-N 1-(methoxymethyl)pyrrolidine Chemical compound COCN1CCCC1 GZPMMQGPHXEMSZ-UHFFFAOYSA-N 0.000 description 1
- JHMKKNJCOSITDU-UHFFFAOYSA-N 1-(phenylmethoxymethyl)pyrrolidine Chemical compound C1CCCN1COCC1=CC=CC=C1 JHMKKNJCOSITDU-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- ZLSOONVQLWLPMF-UHFFFAOYSA-M 3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propyl-diethyl-methylazanium;dibromide Chemical compound [Br-].[Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZLSOONVQLWLPMF-UHFFFAOYSA-M 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 101710111176 5'-methylthioadenosine nucleosidase Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IBCFXJUTCBHRBV-UHFFFAOYSA-N 9-deazaadenine Chemical group NC1=NC=NC2=CC=N[C]12 IBCFXJUTCBHRBV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- ZUNBITIXDCPNSD-LSRJEVITSA-N S-adenosylmethioninamine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CCCN)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZUNBITIXDCPNSD-LSRJEVITSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000610375 Sparisoma viride Species 0.000 description 1
- 108010071698 Spermine synthase Proteins 0.000 description 1
- 102100037616 Spermine synthase Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- MEFKEPWMEQBLKI-LNQOTXDUSA-N [3H]C(N1[C@@H]([C@@H]2O)O[C@H](C[S+](C)CC[C@@H](C([O-])=O)N)[C@H]2O)=NC2=C1N=C([3H])N=C2N Chemical compound [3H]C(N1[C@@H]([C@@H]2O)O[C@H](C[S+](C)CC[C@@H](C([O-])=O)N)[C@H]2O)=NC2=C1N=C([3H])N=C2N MEFKEPWMEQBLKI-LNQOTXDUSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 125000001828 phenalenyl group Chemical group C1(C=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- GUFUWKKDHIABBW-UHFFFAOYSA-N pyrrolidin-1-ylmethanol Chemical compound OCN1CCCC1 GUFUWKKDHIABBW-UHFFFAOYSA-N 0.000 description 1
- WGIFQGWGGQBINH-UHFFFAOYSA-N pyrrolidin-1-ylmethyl acetate Chemical compound CC(=O)OCN1CCCC1 WGIFQGWGGQBINH-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000018612 quorum sensing Effects 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001391 thioamide group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Abstract
The present invention relates to methods of treating cancer by administering to a patient in need thereof one or more inhibitors of 5'-methylthioadenosine phosphorylase (MTAP). In particular, the invention relates to methods of treating prostate cancer or head and neck cancer. HALinda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02106
Description
AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Applicant(s): Albert Einstein College of Medicine of Yeshiva University and Industrial Research Limited Invention Title: METHODS OF TREATING CANCER The following statement is a full description of this invention, including the best method of performing it known to me/us: -2 METHODS OF TREATING CANCER STATEMENT OF GOVERNMENT SUPPORT 5 The invention disclosed herein was made with U.S. Government support under National Institutes of Health (NIH) grant number number GM41916. Accordingly, the U.S. Government has certain rights in this invention. 10 TECHNICAL FIELD The present invention relates to methods of treating cancer by administering to a patient in need thereof one or more inhibitors of 5'-methylthioadenosine phosphorylase (MTAP). In particular, the invention relates to methods of treating prostate cancer or 15 head and neck cancer. BACKGROUND Certain nucleoside analogues have been identified as potent inhibitors of 5' 20 methylthioadenosine phosphorylase (MTAP) and 5'-methylthioadenosine nucleosidase (MTAN). These are the subject of WO 03/080620. Compounds where the location of the nitrogen atom in the sugar ring is varied or where two nitrogen atoms form part of the sugar ring, have also been identified as 25 inhibitors of MTAP and MTAN. These compounds are described in WO 2004/018496. MTAP and MTAN function in the polyamine biosynthesis pathway, in purine salvage in mammals, and in the quorum sensing pathways in bacteria. MTAP catalyses the reversible phosphorolysis of methylthioadenosine (MTA) to adenine and 5-methylthio 30 cx-D-ribose-1-phosphate (MTR-1P). MTAN catalyses the reversible hydrolysis of MTA to adenine and 5-methylthio-a-D-ribose and of S-adenosyl-L-homocysteine (SAH) to adenine and S-ribosyl-homocysteine (SRH). The adenine formed is subsequently recycled and converted into nucleotides. Essentially, the only source of free adenine H:\Linda\Keepspec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -3 in the human cell is a result of the action of these enzymes. The MTR-1P is subsequently converted into methionine by successive enzymatic actions. MTA is a by-product of the reaction involving the transfer of an aminopropyl group 5 from decarboxylated S-adenosylmethionine to putrescine during the formation of spermidine. The reaction is catalyzed by spermidine synthase. Likewise, spermine synthase catalyses the conversion of spermidine to spermine, with concomitant production of MTA as a by-product. The spermidine synthase is very sensitive to product inhibition by accumulation of MTA. Therefore, inhibition of MTAP or MTAN 10 severely limits the polyamine biosynthesis and the salvage pathway for adenine in the cells. Although MTAP is abundantly expressed in normal cells and tissues, MTAP deficiency due to a genetic deletion has been reported with many malignancies. The loss of 15 MTAP enzyme function in these cells is known to be due to homozygous deletions on chromosome 9 of the closely linked MTAP and p16/MTS1 tumour suppressor gene. As absence of p16/MTS1 is probably responsible for the tumour, the lack of MTAP activity is a consequence of the genetic deletion and is not causative for the cancer. However, the absence of MTAP alters the purine metabolism in these cells so that 20 they are mainly dependent on the de novo pathway for their supply of purines. MTA has been shown to induce apoptosis in dividing cancer cells, but to have the opposite, anti-apoptotic effect on dividing normal cells such as hepatocytes (E. Ansorena et al., Hepatology, 2002, 35: 274-280). 25 MTAP inhibitors may therefore be used in the treatment of cancer. Such treatments are described in WO 03/080620 and WO 2004/018496. The need for new cancer therapies remains ongoing. For some prevalent cancers the 30 treatment options are still limited. Prostate cancer, for example, is the most commonly diagnosed non-skin cancer in the United States. Current treatment options include radical prostatectomy, radiation therapy, hormonal therapy, and watchful waiting. H:\Linda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -4 Although the therapies may offer successful treatment of an individual's condition, the pitfalls are quite unfavorable and lead to a decrease in a man's overall quality of life. Surgery may inevitably result in impotence, sterility, and urinary incontinence. Side effects associated with radiation therapy include damage to the bladder and rectum as 5 well as slow-onset impotence. Hormonal therapy will not cure the cancer and eventually most cancers develop a resistant to this type of therapy. The major risk associated with watchful waiting is that it may result in tumour growth, cancer progression and metastasis. It is therefore desirable that a better treatment option is made available to patients diagnosed with prostate cancer. 10 It is an object of the invention to provide a method of treating cancer, particularly prostate or head and neck cancer, or at least to provide a useful choice. STATEMENTS OF INVENTION 15 Ina first aspect, the invention provides a method of treating cancer comprising administering to a patient in need thereof a compound of the formula (1): Z
CH
2 V W x Y 20 OH (I) wherein: V is selected from CH 2 and NH, and W is selected from NR' and NR 2 ; or V 25 is selected from NR 1 and NR 2 , and W is selected from CH 2 and NH; X is selected from CH 2 and CHOH in the R or S-configuration; H:Linda\Keepkspec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -5 Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH, NR' and NR 2 then Y is hydrogen; Z is selected from hydrogen, halogen, hydroxy, SQ, OQ and Q, where Q is 5 alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; R' is a radical of the formula (II) 10 B H N N E D G
R
2 is a radical of the formula (111) B N N A) N E / D 15 :o G A is selected from N, CH and CR 3 , where R 3 is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from 20 hydroxy and halogen; or R 3 is hydroxyl, halogen, NH 2 , NHR 4 , NR 4
R
5 ; or
SR
6 , where R 4 , R 5 and R are alkyl, aralkyl or aryl groups, each of which is optionally substituted with one or more substituents selected from hydroxy and halogen; H:\Linda\Keep~spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 6 B is selected from NH 2 and NHR , where R 7 is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy and halogen; 5 D is selected from hydroxy, NH 2 , NHR 8 , hydrogen, halogen and SCH 3 , where R 8 is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy and halogen; 10 E is selected from N and CH; G is selected from CH 2 and NH, or G is absent, provided that where W is NR or NR 2 and G is NH then V is CH 2 , and provided that where V is NR 1 or NR 2 and G is NH then W is CH 2 ; 15 or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof. Preferably the cancer is prostate cancer or head and neck cancer. 20 In another aspect, the invention provides a method of treating cancer comprising administering to a patient in need thereof a compound of the formula (1): H NH 2 N \ lN Z N N HO (I) 25 where Z is selected from SQ and Q, where Q is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof; 6a in an amount effective to kill a cancer cell. In another aspect the present invention provides the use of an effective amount of a compound of the formula (I): H NH 2 N \ ' N Z N N v HO 5 (I) where Z is selected from SQ and Q, where Q is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; 10 or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof; in the manufacture of a medicament for treating cancer, wherein the medicament comprises the compound of formula (I) in an amount effective to kill a cancer cell. 15 In another aspect, the invention provides the use of an effective amount of a compound of the formula (VIII): H NH 2 N NN N HO OH (VIll) 20 where T is aryl, aralkyl or alkyl, each of which is optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, carboxy or straight- or branched-chain Cr1C6 alkyl; 6b or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof; in the manufacture of a medicament for treating cancer, wherein the medicament comprises the compound of formula (VIII) in an amount effective to kill a cancer cell. 5 In another aspect, the invention provides a method of treating cancer comprising administering to a patient in need thereof a compound of the formula (IV): Z
CH
2 V x Y 10 OH (IV) wherein: -7 V is selected from CH 2 and NH, and W is selected from NR and NR 2 ; orV is selected from NR' and NR 2 , and W is selected from CH 2 and NH; X is selected from CH 2 and CHOH in the R or S-configuration; 5 Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH, NR 1 and NR 2 then Y is hydrogen; Z is selected from hydrogen, halogen, hydroxy, SQ, OQ and Q, where Q is 10 alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy;
R
1 is a radical of the formula (V) 15 B H N N E: D ~-G (V)
R
2 is a radical of the formula (VI) B N N A AN E 20 :-G (VI) H:\Unda\Keeplspec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -8 A is selected from N, CH and CR 3 , where R 3 is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy and halogen; or R 3 is hydroxyl, halogen, NH 2 , NHR 4 , NR 4 R'; or
SR
6 , where R 4 , R 5 and R6 are alkyl, aralkyl or aryl groups, each of which is 5 optionally substituted with one or more substituents selected from hydroxy and halogen; B is selected from NH 2 and NHR , where R 7 is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from 10 hydroxy and halogen; D is selected from hydroxy, NH 2 , NHR 8 , hydrogen, halogen and SCH 3 , where R 8 is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy and halogen; 15 E is selected from N and CH; G is selected from CH 2 and NH, or G is absent, provided that where W is
NR
1 or NR 2 and G is NH then V is CH 2 , and provided that where V is NR 1 20 or NR 2 and G is NH then W is CH 2 ; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof; 25 provided that the compound (3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy 4-(methylthiomethyl)pyrrolidine is excluded. Preferably Z is SQ. 30 Preferably Q is an alkyl group, optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy. It is further preferred that Q is a C1-C alkyl group, optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy. Most preferably Q is a methyl group H:\Linda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -9 Alternatively it is preferred that Z is not methylthio. It is also preferred that Q is an aryl group, optionally substituted with one or more 5 substituents selected from hydroxy, halogen, methoxy, amino, or carboxy. More preferably Q is a phenyl or benzyl group, optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy. Preferably G is CH 2 . It is also preferred that V is CH 2 and W is NR'. It is further 10 preferred that B is NH 2 . It is also preferred that D is H, and it is preferred that A is CH. Preferably any halogen is chlorine or fluorine. In another aspect, the invention provides a method of treating cancer comprising 15 administering to a patient in need thereof a compound of the formula (VII): H NH 2 N N J\S N Nl-/ HO (VIl) where J is aryl, aralkyl or alkyl, each of which is optionally substituted with one or 20 more substituents selected from hydroxy, halogen, methoxy, amir o, or carboxy. Preferably the cancer is prostate cancer or head and neck cancer. Preferably J is C-C 7 alkyl. More preferably J is methyl, ethyl, n-propyl, i-propyl, n 25 butyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl or cycloheptyl. It is also preferred that J is phenyl, optionally substituted with one or more halogen substituents. More preferably J is phenyl, p-chlorophenyl, p-fluorophenyl or m chlorophenyl. H:\Linda\Keep\spec\P60051 PROVISIONAL SPECIFI ZATION (10).DOC 24/02/06 -10 It is also preferred that J is heteroaryl. More preferably J is 4-pyridyl. It is also preferred that J is aralkyl. More preferably j is benzylthio. Preferably J is -CH 2
CH(NH
2 )COOH. In another aspect, the invention provides a method of treating cancer comprising administering to a patient in need thereof a compound of the formula (VIII): H NH 2 N S\ N N S _ N X HO OH (VIII) where T is aryl, aralkyl or alkyl, each of which is optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, carboxy or straight- or branched-chain C-C 6 alkyl; Preferably the cancer is prostate cancer or head and neck cancer. Preferably T is C-C 6 alkyl, optionally substituted with one or more substituents selected from halogen and hydroxyl. More preferably T is methyl, ethyl, 2-fluoroethyl, or 2-hydroxyethyl. Most preferably T is methyl. It is also preferred that T is aryl, optionally substituted with one or more substituents selected from halogen or straight-chain 0 1
-C
6 alkyl. More preferably T is phenyl, naphthyl, p-tolyl, m-tolyl, p-chlorophenyl, m-chlorophenyl or p-fluorophenyl. It is also preferred that T is aralkyl. More preferably T is benzyl. 4732175_1 (GHMatters) P60051.AU 7l Preferably the compound of formula (1) is: (3R,4R)-1 -[(8-aza-9-deazaadenin-9-y)methyl]-3-hyd roxy-4 (hydroxymethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(2-phenylethiyl)pyrrolidine; 5 (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (benzylthiomethyl)pyrrolidine; (3RS)-1 -[(8-aza-9-deazaadenin-9-yl) methyl]-3-hyd roxy-4 (benzylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hyd roxy-4-(4 10 chlorophenylthiomethyl)pyrrolidine; (3R,4R)-1 -[(9-deazaadenin-9-yl) methyll-3-acetoxy-4 (acetoxymethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl) methyl]-3-hydroxy-4-(n butylthiomethyl)pyrrolidine; 15 (3R,4S)-1 -[(9-deazaadenin-9-y) methyl]-3-hyd roxy-4-(4 fluorophenylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(n propylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 20 (cycl ohexylth io methyl) py rrolid ine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(3 ch loro phenylth iomnethyl) pyrrol id ine; (3R,4S)-1 -[(9-deazaadenin-9-y)methylJ-3-hydroxy-4 (ethylth iornethyl) pyrrolid ine; 25 (3R,4S)-1 -[(9-deazaadenin-9-y)methyl]-3-hydroxy-4 (phenylthiomethyl)pyrrolidine; (3R 1 4S)-1 -[(9-deazaadenin-9-yI) methyl]-3-hyd roxy-4-(4 pyridylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-n-propylpyrrolidine; 30 (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (homocysteinylmethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (benzyloxymethyl)pyrrolidine; H:\LindaKeep~spec\P6OO51 PROVISIONAL SPECIFICATION (1O).OOC 24/02/06 -12 (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(i propylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (methoxymethyl)pyrrolidine; 5 (3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (cyclohexylmethylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (cycloheptylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 10 (cyclopentylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (cyclobutylthiomethyl)pyrrolidine. 15 The compounds defined above may be administered orally, parenterally, by inhalation, topically, rectally, nasally, buccally or via an implanted reservoir. Preferably the compounds are administered orally. BRIEF DESCRIPTION OF THE FIGURES 20 Figure 1a shows the survival of mouse prostate cancer cells (RM1) against increasing concentrations of compound (2) [(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (methylthiomethyl)pyrrolidine], either in the presence or absence of MTA. Figure 1b shows the survival of human prostate cancer cells (PC3) against increasing 25 concentrations of compound (2) [(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (methylthiomethyl)pyrrolidine], either in the presence or absence of MTA. Figure 2 is a time dependent proliferation curve, showing the effect of compound (2) [(3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine] 30 and MTA on human prostate cancer cells (PC3). Figure 3 is a time dependent proliferation curve, showing the effect of compound (2) [(3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine] and MTA on SCC25 cells. H:\Linda\Keepspec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24102/06 -13 Figure 4 is a time dependent proliferation curve, showing the effect of compound (2) [(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine] and MTA on FaDu cells. 5 Figure 5 shows phase contrast photographs of FaDu cells after 5 days of treatment with compound (2) [(3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (methylthiomethyl)pyrrolidine] and MTA. 10 Figure 6 shows a cell cycle and apoptosis analysis of FaDu cells after 6 days of treatment with compound (2) [(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (methylthiomethyl)pyrrolidine] and MTA; (1) untreated results: G1 83.66%, S 8.08%, G2 8.26%, Apoptosis 6.06%; (2) treated with MTA results: G1 79.67%, S 10.42%, G2 9.91%, Apoptosis 6.66%; (3) treated with compound (3) results G1 72.06%, S 15 17.98%, G29.96%, Apoptosis 7.89%; (4) treated with MTA + compound (3) results G1 8.26%, S 31.25%, G2 60.49%, Apoptosis 29.41%. Figures 7 to 19 show oral and IP availability of selected compounds that may be used in the methods of the invention. 20 Figure 20 shows the effects of compound 1 [(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3 hydroxy-4-(benzylthiomethyl)pyrrolidine] on FaDu xenografts in NOD-SCID mice. Figure 21 shows representative tumours from each of the treatment cohorts for the 25 above NOD-SCID mouse study. Figure 22 shows MRI images of TRAMP mice (Panels A and B: Control TRAMP (transgenic adenocarcinoma of mouse prostate) mice, Panels E and F: TRAMP mice treated with 1 mM Compound 1 [(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 30 (benzylthiomethyl)pyrrolidine]) Figure 23 shows that compound (2) and MTA alter polyamine levels and induce cytostasis in PC3 cells (PUT=putrescine, SPD=spermidine, SPN=spermine). PC3 cells were cultured and treated in triplicate as follows: untreated control, 20 pM substrate H:Linda\Keepkspec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -14 (MTA) alone, 1 pM compound (2) alone, or a combination of both substrate and inhibitor. Both cells and spent media were harvested at 1, 6, and 12 days for polyamine analysis by HPLC fluorescence. 5 Figure 24 shows that compound (2) reduces tumour growth and metastasis in TRAMP mice, but does not alter polyamine levels in vivo. C56Bl/6 mice were treated with 100 gM compound (2) via their drinking water and sacrificed at 24, 48 hours, and 7 days. Livers were immediately removed for polyamine analysis. TRAMP mice were treated approximately 6-8 months with 100 p.M compound (2) via their drinking water and 10 control sacrificed. Livers were removed for polyamine analysis. DETAILED DESCRIPTION Definitions 15 The term "alkyl" is intended to include straight- and branched-chain alkyl groups, as well as cycloalkyl groups. The same terminology applies to the non-aromatic moiety of an aralkyl radical. Examples of alkyl groups include: methyl group, ethyl group, n propyl group, iso-propyl group, n-butyl group, iso-butyl group, sec-butyl group, t-butyl 20 group, n-pentyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2 dimethylpropyl group, 1-ethylpropyl group, 2-ethylpropyl group, n-hexyl group and 1 methyl-2-ethylpropyl group. The term "aryl" means an aromatic radical having 6 to 18 carbon atoms and includes 25 heteroaromatic radicals. Examples include monocyclic groups, as well as fused groups such as bicyclic groups and tricyclic groups. Some examples include phenyl group, indenyl group, 1-naphthyl group, 2-naphthyl group, azulenyl group, heptalenyl group, biphenyl group, indacenyl group, acenaphthyl group, fluorenyl group, phenalenyl group, phenanthrenyl group, anthracenyl group, cyclopentacyclooctenyl 30 group, and benzocyclooctenyl group, pyridyl group, pyrrolyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, triazolyl group, tetrazolyl group, benzotriazolyl group, pyrazolyl group, imidazolyl group, benzimidazolyl group, indolyl group, isoindolyl group, indolizinyl group, purinyl group, indazolyl group, furyl group, pyranyl HALinda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -15 group, benzofuryl group, isobenzofuryl group, thienyl group, thiazolyl group, isothiazolyl group, benzothiazolyl group, oxazolyl group, and isoxazolyl group. The term "halogen" includes fluorine, chlorine, bromine and iodine. 5 The compounds are useful for the treatment of certain diseases and disorders in humans and other animals. Thus, the term "patient" as used herein includes both human and other animal patients. 10 The term "prodrug" as used herein means a pharmacologically acceptable derivative of the compound of formula (1), (IV), (VII) or (Vill), such that an in vivo biotransformation of the derivative gives the compound as defined in formula (1), (IV), (VII) or (Vill). Prodrugs of compounds of formulae (1), (IV), (VII) or (VIII) may be prepared by modifying functional groups present in the compounds in such a way that the 15 modifications are cleaved in vivo to give the parent compound. Prodrugs include compounds of formulae (1), (IV), (VII) and (Vill), tautomers thereof and/or pharmaceutically acceptable salts thereof, which include an ester functionality, or an ether functionality. It will be clear to the skilled person that the compounds of 20 formulae (1), (IV), (VII) and (Vill) may be converted to corresponding ester or ether prodrugs using known chemical transformations. Suitable prodrugs include those where the hydroxyl groups of the compounds of formula (1), (IV), (VII) or (Vill) are esterified to give, for example, a primary hydroxyl 25 group ester of propanoic or butyric acid. Other suitable prodrugs are alkycarbonyoxymethyl ether derivatives on the hydroxyl groups of the compounds of formula (1), (IV), (VII) or (Vill) to give, for example, a primary hydroxyl group ether with a pivaloyloxymethyl or a propanoyloxymethyl group. 30 The term "pharmaceutically acceptable salts" is intended to apply to non-toxic salts derived from inorganic or organic acids, including, for example, the following acid salts: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, H:\Linda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -16 glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, p 5 toluenesulfonate, salicylate, succinate, sulfate, tartrate, thiocyanate, and undecanoate. It will be appreciated that the representation of a compound of formula (1) or (IV) where B and/or D is a hydroxy group, is of the enol-type tautomeric form of a corresponding amide, and this will largely exist in the amide form. The use of the enol-type 10 tautomeric representation is simply to allow fewer structural formulae to represent the compounds of the invention. Similarly, it will be appreciated that the representation of a compound of formula (1) or (IV), where B and/or D is a thiol group, is of the thioenol-type tautomeric form of a 15 corresponding thicamide, and this Will largely exist in the thioamide form. The use of the thioenol-type tautomeric representation is simply to allow fewer structural formulae to represent the compounds of the invention. Detailed Description of the Invention 20 The present invention relates to methods of treating cancer by administering to a patient in need thereof one or more inhibitors of 5'-methylthioadenosine phosphorylase (MTAP). In particular, the invention relates to methods of treating certain cancers, such as prostate cancer or head and neck cancer. 25 Suitable MTAP inhibitors which may be employed in the method of the present invention and the methods for preparing these inhibitors are described in WO 03/080620 and WO 2004/018496. 30 Certain MTAP inhibitor compounds are surprisingly effective for treating prostate and head and neck cancers. These are compounds of general formula (VII). H:\Linda\Keepkspec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -17 H NH 2 N N S N N HO (VI1) This sub-class of MTAP inhibitors incorporates an adenine-like base moiety and a pyrrolidine moiety having an alkyl- aryl- or aralkylthiomethyl group at the 4-position. 5 Other MTAP inhibitor compounds are also surprisingly effective for treating prostate and head and neck cancers. These are compounds of general formula (VIII). H NH 2 N T N S N N HO OH (Vill) 10 This sub-class of MTAP inhibitors also incorporates the adenine-like base moiety but has an iminoribitol moiety with an alkyl- aryl- or aralkylthiomethyl group at the 5' position. 15 Examples of the first sub-class of inhibitors include compounds (1) and (2). H NH 2
NH
2 Ns N N HO HO Compound (1) Compound (2) BT-DADMe-ImmA MT-DADMe-ImmA H:\Linda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -18 The present studies show that compounds (1) and (2) are effective both in vitro and in vivo against a variety of cell lines (PC3, RM1, SCC25 and FaDu). These compounds are therefore particularly useful in the treatment of prostate and head and neck cancers. 5 The MTAP inhibitor compounds inhibit cell growth in vitro of the prostate cancer cell lines PC3 and RM1 and the head and neck cancer cell lines SCC25 and FaDu. An enhanced cell-killing effect is seen in vitro with combined administration of the MTAP inhibitor compound plus MTA. Examples of this effect are shown in Figures 1 to 6. 10 Furthermore, the inhibitor compounds, when co-administered with MTA, exhibit a cytostatic effect on PC3 cells in vitro. In order to determine whether the inhibition is selective for malignant cells, normal 15 human fibroblast cells (GM02037) were also treated with compound (2) and MTA for 3 weeks. No cytotoxicity was observed. Compound (2) is therefore cytotoxic for human HNSCC (human head and neck squamous cell carcinoma) cells at doses that exhibit minimal toxicity for normal cells. This selectivity is a further indication that the MTAP inhibitors described above are useful agents for the treatment of head and neck 20 cancer. The present in vivo studies further demonstrate the surprising efficacy of the compounds. In a NOD-SCID mouse model, compound (2) significantly delays the growth of established FaDu xenografts. The effect is seen either with or without co 25 administration of the inhibitor compound with MTA. In addition, prostate cancer progression in the TRAMP mouse model is inhibited in mice treated with compound (1), either alone or in combination with MTA. 30 An example of the second sub-class of inhibitors is compound (3). H:\Unda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -19 H NH 2 N N S-N N HO Compound (3) MT-ImmA This compound also inhibits prostate cancer progression in the TRAMP mouse model, when administered either alone or in combination with MTA. 5 For the above in vivo models, the inhibitor compounds exhibit activity when administered with exogenous MTA and when administered alone. There is not a significant enhancement observed when the inhibitors are administered together with MTA. However, the in vitro results clearly demonstrate a surprising enhancement in 10 activity when the inhibitors are administered in conjunction with MTA. Thus, the combined administration method provides a potential alternative treatment method for patients suffering from cancer, where the administration of an MTAP inhibitor is indicated. 15 The MTAP inhibitor compounds of formulae (1), (IV), (VII) and (Vill) (in particular the compounds of formulae (VII) and (Vill)) provide an effective alternative treatment option for cancer sufferers, especially for patients diagnosed with prostate and head and neck cancers. 20 General Aspects The MTAP inhibitor compounds are useful in both free base form and in the form of salts. 25 Figures 7, 9, 10, 12, 13, 15 and 16-19 show that the MTAP inhibitor compounds used in the methods of the present invention are orally available, and may therefore be formulated for oral administration. The compounds may also be administered by other routes. For example, the MTAP inhibitors may be administered to a patient orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally or via an H:\Linda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 - 20 implanted reservoir. The amount of compound to be administered will vary widely according to the nature of the patient and the nature and extent of the disorder to be treated. Typically the dosage for an adult human will be in the range less than 1 to 1000 milligrams, preferably 0.1 to 100 milligrams. The specific dosage required for 5 any particular patient will depend upon a variety of factors, including the patient's age, body weight, general health, sex, etc. For oral administration the active compounds can be formulated into solid or liquid preparations, for example tablets, capsules, powders, solutions, suspensions and 10 dispersions. Such preparations are well known in the art as are other oral dosage regimes not listed here. In the tablet form the compounds may be tableted with conventional tablet bases such as lactose, sucrose and corn starch, together with a binder, a disintegration agent and a lubricant. The binder may be, for example, corn starch or gelatin, the disintegrating agent may be potato starch or alginic acid, and the 15 lubricant may be magnesium stearate. For oral administration in the form of capsules, diluents such as lactose and dried cornstarch may be employed. Other components such as colourings, sweeteners or flavourings may be added. When aqueous suspensions are required for oral use, the active ingredient may be 20 combined with carriers such as water and ethanol, and emulsifying agents, suspending agents and/or surfactants may be used. Colourings, sweeteners or flavourings may also be added. The compounds may also be administered by injection in a physiologically acceptable 25 diluent such as water or saline. The diluent may comprise one or more other ingredients such as ethanol, propylene glycol, an oil or a pharmaceutically acceptable surfactant. The compounds may also be administered topically. Carriers for topical administration 30 of the compounds include mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. The compounds may be present as ingredients in lotions or creams, for topical administration to skin or mucous membranes. Such creams may contain the active compounds suspended or dissolved in one or more pharmaceutically acceptable H:\Linda\Keepkspec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02106 - 21 carriers. Suitable carriers include mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The compounds may further be administered by means of sustained release systems. 5 For example, they may be incorporated into a slowly dissolving tablet or capsule. Examples of suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences (Mack Publishing Company). 10 EXAMPLES Inhibitor Compounds Inhibitors of MTAP were synthesized as described earlier (Singh, V., Shi, W., Evans, G. B., Tyler, P. C., Furneaux, R H, Almo, S C, and Schramm, V L (2004) Biochemistry 43, 9-18; Evans G B, Furneaux R H, Lenz D H, et 15 al., J Med Chem 2005:48, 4679-89). Solutions were standardized by the UV absorbance of the 9-deazaadenine ring. Sterile solutions of inhibitors were prepared by filtration. 20 Example 1: Clonogenic Assays (Figure 1) PC3 cells were grown in equal (1:1) portions of Dulbecco's modified Eagle's medium and F12 containing 10% fetal bovine serum, 10 U/mL penicillin-G and 10 pg/mL streptomycin in monolayers to near confluency at 37 *C. Cells were lysed in 50 mM 25 sodium phosphate pH 7.5, 10 mM KCI and 0.5% Triton X-100. Example 2: Effect of Compound 2 and MTA on PC3 cells (Figure 2) PC3 cells were maintained in MEM Eagle's media supplemented with 10% fetal bovine 30 serum, 100 units/ml penicillin, 100 gg/mL streptomycin, 0.1 mM non essential amino acids and 1 mM sodium pyruvate. Cell survival was evaluated using the WST-1 assay (Kicska G A, long Li, Horig H, et al. Proc NatlAcad Sci USA 2001;98:4593-98). Cells were seeded onto 96 well plates at a HALinda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).0OC 24/02/06 - 22 density of 104 cells per well, with either no additions, 1 IM compound 2, 20 pLM MTA or 1 jiM compound 2 + 20 jiM MTA. IC 50 was determined following the manufacturer's protocol (Roche Applied Science, IN). Cells were grown and measured in triplicate or quadruplicate and the error bars show the mean ± SD of the multiple samples. 5 Example 3: Effect of Compound 2 and MTA on SCC25 cells (Figure 3) SCC25 cells were maintained in MEM Eagle's media supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 pag/mL streptomycin, 0.1 mM non essential 10 amino acids and 1 mM sodium pyruvate. Cell survival was evaluated using the WST-1 assay (Kicska G A, long Li, Horig H, et al. Proc Nat/ Acad Sci USA 2001;98:4593-98). Cells were seeded onto 96 well plates at a density of 10 4 cells per well, with either no additions, 1 piM MT- compound 2, 20 pM 15 MTA or 1 ptM compound 2 + 20 ptM MTA. IC 50 was determined following the manufacturer's protocol (Roche Applied Science, IN). Cells were grown and measured in triplicate or quadruplicate and the error bars show the mean t SD of the multiple samples. 20 Example 4: Effect of MT-DADMe-ImmA (Compound 1) and MTA on FaDu cells (Figure 4) FaDu cells were maintained in MEM Eagle's media supplemented with 10% fetal bovine serum, 100 units/mI penicillin, 100 tg/mL streptomycin, 0.1 mM non essential 25 amino acids and 1 mM sodium pyruvate. Cell survival was evaluated using the WST-1 assay (Kicska G A, long Li, Horig H, et al. Proc Nat Acad Sci USA 2001;98:4593-98). Cells were seeded onto 96 well plates at a density of 10 4 cells per well, with either no additions, 1 ptM compound 2, 20 piM MTA or 30 1 jiM compound 2 + 20 jiM MTA. IC 50 was determined following the manufacturer's protocol (Roche Applied Science, IN). Cells were grown and measured in triplicate or quadruplicate and the error bars show the mean ± SD of the multiple samples. Example 5: Phase Contrast Microscopy of FaDu Cells (Figure 5) HALinda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 - 23 FaDu cells were subjected to six days in culture using the same conditions described as for Example 4. 5 Example 7: Cell Cycle and Apoptosis Analysis of FaDu cells (Figure 6) FaDu cells were subjected to six days in culture using the same conditions described as for Example 4, before staining with propidium bromide and FACS cell sorting analysis. 10 Example 8: Oral Availability (Method for Compound (2)) Two groups of 3 C57BL6 mice received a single oral dose of compound (2) dissolved in sterile, deionized water, pippeted onto a crumb of food. Treated food was fed to 15 each mouse individually under close observation at time zero. Two different single doses of inhibitor were administered: 50 jig and 100 jg. Mice were individually fed and closely observed for consumption of food. At specific time points, 4 pL blood samples were collected from the tail vein. The blood was mixed with 4ptL 0.6% Triton X-100 in PBS and stored at -80 0 C until time of analysis. 20 The amount of adenine produced was measured by the following MTAP activity assay: Cells were harvested, washed three times with PBS and lysed with RIPA buffer. The reaction mixture for MTAP activity assays contained the following: - 75 pig protein 25 from cell lysates, 50 mM HEPES pH 7.4, 50 pM MTA, and 20,000 dpm [2,8-3H]MTA. Labeled MTA was synthesized from [2,8-3H]S-adenosylmethionine by a known method. Products of the MTAP reaction were resolved using TLC silica plates with 1 M ammonium acetate, pH 7.55, and 5% isopropanol. Adenine spots were excised and counted for label incorporation. 30 Example 9: FaDu Xenograft Studies (Figures 20 and 21) FaDu cells were injected into the dorsum of the foot of NOD-SCID mice. Groups were fed with 250 and 500 piM of compound 2 p.o. or given i.p. injections of 100 pil of H:\Linda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24102/06 - 24 compound 2, daily. Differences between treatment cohorts were determined using Student's t test. Compound 2 significantly delayed the growth of established FaDu xenografts. 5 Example 10: MRI Studies (Figure 22) MRI experiments were performed using a 9.4T 21 cm bore horizontal bore magnet (Magnex Scientific) Varian INOVA MRI system (Fremont, CA) equipped with a 28 mm inner diameter quadrature birdcage coil. Mice were anesthetized with isoflurane 10 inhalation anesthesia (1-1.5% in 100% 02 administered via a nose cone) and positioned in the MRI coil. Body temperature was maintained (37-38"C) using a homeothermic warming system. After acquiring scout images, multi-slice spin-echo imaging with an echo time of 18 ms and a repetition time of 400ms ms was performed. A 40 mm field of view with a 256 x 256 matrix size was used. Nine to 15 slices along 15 the transverse, sagittal, and coronal planes were acquired in each multi-slice experiment with a slice thickness of 1 mm and the gap between slices of 0.5 mm. MRI data were processed off-line with MATLAB-based MRI analysis software. Example 11: Quantitation of Polyamines in Cells, Spent Media and Tissue 20 Samples (Figure 23) Spent media and perchloric acid extracts of both PC3 cells and tissue samples were subjected to purification via cation exchange chromatography and dansyl-derivatized with minor changes. Disposable 10 ml BIO-RAD columns were centrifuged at 4,000 25 rpm for 3 minutes. Sodium carbonate used for derivatization was adjusted to pH 9.3 and the concentration of dansyl-chloride was adjusted to 100 mM. Dansyl-polyamines were quantitated by a Waters HPLC/ Fluorescence system. A Phenomenex Luna 5 pt C18 column was used with a mobile phase of 30% acetonitrile in a 50 mM ammonium acetate buffer at pH 6.8 (eluent A) and 100% acetonitrile (eluent B). Fluorescence 30 detection was monitored by excitation at 338 nm and emission at 500 nm. Example 12: Treatment of TRAMP Mice (Table 1, Figure 22) H:\Linda\Keep~spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -25 Short-Term: Mice were treated with sterile solutions of 100 pM compound (2) (pH -6.4). Water bottles were autoclaved prior to filling with sterile inhibitor solutions. Mice were sacrificed at 1, 2, and 7 days, with three mice in each group, with the control group sacrificed after 7 days. Livers were immediately removed upon sacrifice 5 for polyamine analysis, conducted as described above. Long-Term: Sterile solutions of 100 tM compound (2) (pH -6.4). Water bottles were autoclaved prior to filling with sterile inhibitor solutions. Water consumption was monitored every other day, with fresh inhibitor solution being administered to prevent 10 bacterial growth. Mice were control-sacrificed and tissues (genitourinary system, liver, lungs) were collected for histology and polyamine analysis. Mass and dimensions of excised genitourinary system tumours were recorded. Sections of small intestine were also removed for toxicity analysis via H&E staining. 15 Discussion of the Examples Figure 1 a shows the effect of the addition of compound (2) to cultured mouse prostate cancer cells (RM1). Figure lb shows the effect of the addition of compound (2) to cultured human prostate cancer cells (PC3). Compound (2) was added either alone or 20 in the presence of 20 ptM MTA. Figures 2, 3 and 4 show the effects of MTA alone, compound (2) alone and MTA with compound (2) in time dependent cell proliferation experiments (PC3 cells, SCC25 cells and FaDu cells). The combination of compound (2) and MTA reduces cell proliferation. These data demonstrate that the compounds which are used in the methods of the present invention inhibit cell growth in vitro, when 25 administered in combination with MTA. Figure 5 further demonstrates, showing phase contrast photographs of FaDu cells after 5 days of treatment with compound (2)/compound (2) + MTA, that the inhibitor compound + MTA is effective in inhibiting cell growth. 30 Thus, administration of MTA in circumstances where its degradation by MTAP is inhibited by an MTAP inhibitor leads to greater circulatory and tissue levels of MTA and consequently an enhanced effect in the treatment of cancer. H:\Linda\Keepspec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06 -26 Figure 6 shows that compound (2) in combination with MTA is also effective for stopping cell cycling (for FaDu cells) such that the cells become apoptotic. Figures 20 and 21 show the results of in vivo studies. FaDu cells were injected into the 5 dorsum of the foot of NOD-SCID mice. Groups were fed with 250 and 500 pLM of compound (2) p.o. or given i.p. injections of 100 ptl of 4 mM compound (2), daily. Figure 21 shows representative tumours from each of the treatment cohorts. Differences between treatment cohorts were determined using Student's t test. Figure 20 is a summary of the data for all treatment cohorts. The results show that compound 10 (2) significantly delays the growth of established FaDu xenografts. Longitudinal MRI provides a noninvasive means of monitoring prostate tumour growth in mice (Gupta S, Hastak K, Ahmad N, Lewin J S, Mukhtar H Proc Natl Acad Sci USA 2001 Aug 28;98(18):10350-5; Eng M H, Charles L G, Ross B D, Chrisp C E, Pienta K 15 J, Greenberg N M, Hsu C X, Sanda M G Urology 1999 Dec:54(6):1112-9; Song S K, Qu Z, Garabedian E M, Gordon J I, Milbrandt J, Ackerman J J Cancer Res. 2002 Mar 1:62(5):1555-8.). MRI is used in the present case to evaluate prostate tumour growth and progression 20 longitudinally in TRAMP mice (either untreated or treated with a compound that may be used according the methods of the invention). Mice were imaged approximately monthly from 12-33 weeks of age. Representative MRI images comparing untreated control TRAMP and treated TRAMP mice at approximately 30 weeks of age are shown in Figure 22. 25 Panels A and B show results from control mice. Panel A shows a coronal section through of a 30 week old TRAMP mouse with a large tumour (bright tissue) that weighed 8.76 g upon dissection at 34 weeks of age. The inset shows a more posterior coronal section. The bright tumour is smaller in this section but metastasis to the liver 30 is observed (white arrow). Panel B shows a coronal section through the prostate region of a 30 week old TRAMP mouse. The seminal vesicles (SV) are enlarged. A large tumour (weighing 4.89 g upon dissection at 36 weeks of age) that spanned from the kidney to bladder (BL) is visible in the transverse section shown in the inset (white arrow). H:\Linda\Keep\spec\P60051 PROVISIONAL SPECIFICATION (10),DOC 24/02/06 - 27 Panels E and F show results for mice treated with 1 mM compound (1). Panel E shows a coronal section through the prostate region of a 30 week old treated TRAMP mouse. The tumour, weighing 0.41 g upon dissection at 34 weeks of age, was not observed 5 during the imaging session. Panel F shows a similar section through a 30 week old treated TRAMP mouse that exhibited a 0.64 g tumour upon dissection at 39 weeks of age. The tumour is indicated by the white arrow in the MRI image shown in this panel. Untreated TRAMP mice therefore demonstrate primary prostate tumour growth. 10 However, prostate cancer progression in the TRAMP mouse is inhibited in mice treated with compound (1), either alone or in combination with MTA. Figure 23 shows that compound (2) and MTA, administered together, alter polyamine levels and induce cytostasis in PC3 cells. Combination treatment of PC3 cells with 15 compound (2) and MTA for 1 day resulted in a significant 6-fold increase in intracellular PUT levels (3.03 x 10~3 ± 2.86 x 10-2, combination treated cells vs. 5.04 X 10-2 ± 1.08 x 10-2, control, p= 0.001, pmoles PUT/mg protein), a 2-fold increase in spent media PUT levels [1.19 x 10-3 ± 2.04 x 10, combination treated media vs. 5.85 x 10-2 ± 5.09 x 10-0, control media, p= 0.0001, pmoles PUT/mL spent media, as well as 20 roughly a 2.5-fold increase in intracellular SPD levels (7.19 x 10-3 ± 4.38 x 10-2, combination treated cells vs. 3.05 x 10-3 ± 6.3 x 10-2, control, p=0.001 pmoles SPD/mg protein). SPN levels in combination treated spent media also slightly decreased (p=0.02). After 6 days of treatment, cellular SPN levels were decreased roughly 0.5 fold (4.0 x 10-' ± 7.38 x 10-2, combination treated cells vs. 6.87 x 10~3 ± 9.68 x 10-2, 25 control, p= 0.005, pmoles SPN/mg protein), with both PUT and SPD elevated (p= 0.02 and p= 0.01, respectively in comparison to controls). Most significantly, levels of PUT in spent media were almost double that of the control (2.41 x 10-3 ± 7.35 x 10-1, combination treated spent media vs. 1.31 X 10- 3 ± 0.0, control, p=0.0007, pmoles PUT/mL spent media). By day 12, a significant increase in cellular SPD levels were 30 observed (9.05 x 10-3 ± 1.09 x 10-3, combination treated cells vs. 3.93 x 10-3 ± 8.4 x 10~ , control, p=0.007, pmoles SPD/mg protein), with a corresponding decrease in levels of spent media PUT levels (1.65 x 10-3 ± 2.27 x 10-2, combination treated spent media vs. 2.12 x 10~ 3 ± 9.34 x 10', control media, pmoles PUT/mL spent media, p=0.013). H:\Linda\Keep\spe\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02106 - 28 Intracellular PUT levels in combination treated cells were still significantly higher than controls (p=0.005). Treatment of PC3 cells with compound (2) therefore results in numerous significant 5 alterations in both intracellular and spent media polyamine levels. After 24 hours of treatment, the increase observed in cellular SPD levels as well as putrescine (PUT) cellular and spent media polyamine levels correlates with the effects expected with MTAP inhibition. MTA is accumulating in the cells, beginning to feedback inhibiting SPN synthase, resulting in accumulations of SPD and PUT, with PUT being 10 significantly excreted into the media, and a slight decrease of SPN in the media. By day 6, cellular SPN levels are significantly reduced in combination treated cells, while maintaining the characteristic elevations in levels of PUT and SPD. Treatment of cells for 12 days shows a significant increase in cellular SPD levels and a slight decrease in spent media PUT levels, pointing to the fact that a compensatory pathway has been 15 activated to make up for the block in MTAP. PUT may be being taken up from the media for SPD synthesis. After combination treatment for approximately 2 weeks, PC3 cells display a cytostatic effect, as determined by the clonogenic assay. Initially, it was believed that MTAP inhibition would lead to MTA accumulation, causing feedback inhibition of polyamine biosynthesis, resulting in decreases in cellular 20 proliferation. A halt in cellular proliferation is observed, and it is now believed that this is not due only to polyamine depletion. Figure 24 shows that compound (2) reduces tumour growth and metastasis in TRAMP mice, but does not alter polyamine levels in vivo. Polyamine levels of mice livers are 25 not significantly altered during short-term treatment (Figure 24A). After extended treatment with compound (2) inhibitor solutions, no significant alterations in either TRAMP liver or GUS polyamine levels were detected (Figures 24B and 24C). Mass (Table 1) and dimensions of excised genitourinary system tumors were recorded 30 for all members of the treatment groups. Sections of small intestine were also removed for toxicity analysis via H&E staining. Histology of TRAMP mice revealed all animals showed extensive prostate intraepithelial neoplasia involving most prostate acini. However, the size and incidence of preinvasive tumors, as well as the incidence of invasive cancer and metastasis were all decreased in treated TRAMP mice (Table HALinda\Keep~spec\P60051 PROVISIONAL SPECIFICATION (10).O0C 24/02/06 -29 1). No alterations, inflammations, or irregularities were observed in the intestinal crypts, neither were any hair loss or general GI problems noted, indicating a lack of drug toxicity. 5 Table 1: Summary of results for TRAMP mice treated with compound (2) # Tumor Weeks Metastatic Experimental Animals Size treated Cancer Condition (n) (g) Control 16 4.0 ± 2.8 32 ± 5 44% 100 pM compound (2) 12 1.7 ± 0.8 29 ± 7 8% Although the invention has been described by way of example, it should be 10 appreciated the variations or modifications may be made without departing from the scope of the invention. Furthermore, when known equivalents exist to specific features, such equivalents are incorporated as if specifically referred to in the specification. 15 In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the 20 invention. It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country. H:Linda\Keep~spec\P60051 PROVISIONAL SPECIFICATION (10).DOC 24/02/06
Claims (34)
1. A method of treating cancer comprising administering to a patient in need thereof a compound of the formula (1): H NH 2 N N Z N N HO 5 (I) where Z is selected from SQ and Q, where Q is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; 10 or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof; in an amount effective to kill a cancer cell.
2. A method as claimed in claim 1 where Z is SQ. 15
3. A method as claimed in claim 2 where Z is not methylthio.
4. A method as claimed in claim 2 where Q is an alkyl group, optionally substituted with one or more substituents selected from hydroxy, halogen, 20 methoxy, amino, or carboxy.
5. A method as claimed in claim 2 where Q is an aryl group, optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy. 25
6. A method as claimed in claim 2 where Q is a Cr1C6 alkyl group, optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy. 31
7. A method as claimed in claim 5 where Q is a phenyl or benzyl group, optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy. 5
8. A method as claimed in claim 1 where any halogen is chlorine or fluorine.
9. A method as claimed in claim 1 where Q is C 1 -C 7 alkyl.
10. A method as claimed in claim 1 where Q is methyl, ethyl, n-propyl, i-propyl, n 10 butyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl or cycloheptyl.
11. A method as claimed in claim 1 where Q is phenyl, optionally substituted with one or more halogen substituents. 15
12. A method as claimed in claim 1 where Q is phenyl, p-chlorophenyl, p fluorophenyl or m-chlorophenyl.
13. A method as claimed in claim 1 where Q is heteroaryl. 20
14. A method as claimed in claim 1 where Q is 4-pyridyl.
15. A method as claimed in claim 1 where Q is aralkyl.
16. A method as claimed in claim 1 where Q is benzylthio. 25
17. A method as claimed in claim 1 where Q is -CHCH(NH 2 )COOH.
18. A method of treating cancer comprising administering to a patient in need thereof a compound of the formula (Vill): 30 32 H NH 2 N T I-NN NN HO OH (Vill) where T is aryl, aralkyl or alkyl, each of which is optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, carboxy 5 or straight- or branched-chain C-C6 alkyl; or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof; 10 in an amount effective to kill a cancer cell.
19. A method as claimed in claim 18 where T is C1rC6 alkyl, optionally substituted with one or more substituents selected from halogen and hydroxy. 15
20. A method as claimed in claim 18 where T is methyl, ethyl, 2-fluoroethyl, or 2 hydroxyethyl.
21. A method as claimed in claim 18 where T is methyl. 20
22. A method as claimed in claim 18 where T is aryl, optionally substituted with one or more substituents selected from halogen or straight-chain Cr-C6 alkyl.
23. A method as claimed in claim 18 where T is phenyl, naphthyl, p-tolyl, m-tolyl, p chlorophenyl, m-chlorophenyl or p-fluorophenyl. 25
24. A method as claimed in claim 18 where T is aralkyl.
25. A method as claimed in claim 18 where T is benzyl. 33
26. A method as claimed in claim 1 where the compound of formula (1) is: (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(2-phenylethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (benzylthiomethyl)pyrrolidine; 5 (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(4 chlorophenylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(n butylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(4 10 fluorophenylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(n propylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (cyclohexylthiomethyl)pyrrolidine; 15 (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(3 chlorophenylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (ethylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 20 (phenylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(4 pyridylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-n-propylpyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 25 (homocysteinylmethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(i propylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (cyclohexylmethylthiomethyl)pyrrolidine; 30 (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (cycloheptylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 (cyclopentylthiomethyl)pyrrolidine; (3R,4S)-1 -[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4 35 (cyclobutylthiomethyl)pyrrolidine. 34
27. A method as claimed in any one of claims 1 to 26 where the cancer is prostate cancer. 5
28. A method as claimed in any one of claims 1 to 26 where the cancer is head and neck cancer.
29. A method as claimed in claim 27 or 28 where the compound is administered orally, parenterally, by inhalation, topically, rectally, nasally, buccally or via an 10 implanted reservoir.
30. A method as claimed in claim 29 where the compound is administered orally.
31. The use of an effective amount of a compound of the formula (I): 15 H NH 2 N N Z-N N HO (1) where Z is selected from SQ and Q, where Q is alkyl, aralkyl or aryl, each of which is optionally substituted with one or more substituents selected from 20 hydroxy, halogen, methoxy, amino, or carboxy; or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof; in the manufacture of a medicament for treating cancer, wherein the medicament comprises the compound of formula (I) in an amount effective to kill 25 a cancer cell.
32. The use of an effective amount of a compound of the formula (Vlll): 35 H NH 2 N T NN S N N HO OH (Vill) where T is aryl, aralkyl or alkyl, each of which is optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, carboxy 5 or straight- or branched-chain C-C 6 alkyl; or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof; in the manufacture of a medicament for treating cancer, wherein the medicament comprises the compound of formula (VIII) in an amount effective to 10 kill a cancer cell.
33. The use as claimed in claim 31 or claim 32 where the cancer is prostate cancer or head and neck cancer. 15
34. A method as claimed in claim 1, a method as claimed in claim 18, a use as claimed in claim 31 or a use as claimed in claim 32, substantially as herein described with reference to any of the examples and/or figures.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006200809A AU2006200809B2 (en) | 2006-02-24 | 2006-02-24 | Methods of treating cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006200809A AU2006200809B2 (en) | 2006-02-24 | 2006-02-24 | Methods of treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2006200809A1 AU2006200809A1 (en) | 2007-09-13 |
AU2006200809B2 true AU2006200809B2 (en) | 2013-11-07 |
Family
ID=38515572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006200809A Ceased AU2006200809B2 (en) | 2006-02-24 | 2006-02-24 | Methods of treating cancer |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2006200809B2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004018496A1 (en) * | 2002-08-21 | 2004-03-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside phosphorylases and nucleosidases |
WO2007069923A1 (en) * | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 1'-aza-l-nucleosides |
-
2006
- 2006-02-24 AU AU2006200809A patent/AU2006200809B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004018496A1 (en) * | 2002-08-21 | 2004-03-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside phosphorylases and nucleosidases |
WO2007069923A1 (en) * | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 1'-aza-l-nucleosides |
Also Published As
Publication number | Publication date |
---|---|
AU2006200809A1 (en) | 2007-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8916571B2 (en) | Methods of treating cancer using inhibitors of 5′-methylthioadenosine phosphorylase | |
US20110092521A1 (en) | Methods of Treating Diseases Using Inhibitors of Nucleoside Phosphorylases and Nucleosidases | |
JP7009053B2 (en) | Composition of organic selenium compound and its usage | |
ES2361566T3 (en) | USE OF PARP-1 INHIBITORS. | |
FI91764B (en) | Analogous process for the preparation of acyldoxy ribonucleoside derivatives | |
EP2831047B1 (en) | Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic | |
AU2010276160A1 (en) | Treatment of liver disorders with PI3K inhibitors | |
NZ583824A (en) | Azacytidine analogues and uses thereof | |
CA3012001A1 (en) | Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash) | |
US20070161665A1 (en) | Cancer treatment method | |
US20110003758A1 (en) | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | |
CN106659701B (en) | Ketobutyrate compounds and compositions for the treatment of age-related conditions and disorders | |
WO2009108926A1 (en) | Inhibitors of glycolysis useful in the treatment of brain tumors | |
WO2016163082A1 (en) | Prophylactic/therapeutic agent for virus infections which comprises ala compound | |
CN102083829A (en) | Improved Raf inhibitors | |
TW202033191A (en) | Novel pharmaceutical composition and use thereof | |
AU2006200809B2 (en) | Methods of treating cancer | |
CA2537669C (en) | Inhibitors of nucleoside phosphorylases and nucleosidases for treating cancer | |
WO2020218562A1 (en) | Pharmaceutical composition for preventing or treating treatment-resistant cancer | |
WO2019146129A1 (en) | Pharmaceutical composition for tumor having isocitrate dehydrogenase mutation, antitumor agent and use thereof | |
JP2006298892A (en) | Anticancer agent | |
CN112939947B (en) | PARP7 small molecule inhibitor compound and application thereof | |
WO2021125313A1 (en) | Therapeutic agent containing fused pyrimidine compound as active ingredient | |
JP2023509283A (en) | Synergistic nutritional compositions for improving ATP efficiency | |
EP3878841A1 (en) | Indazole kinase inhibitor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH | Corrigenda |
Free format text: IN VOL 20, NO 10, PAGE(S) 927 UNDER THE HEADING COMPLETE APPLICATIONS FILED - NAME INDEX UNDER THE NAME ALBERT EINSTEIN COLLEGE OF MEDICENE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA UNIVERSITY AND INDUSTRIAL RESEARCH LIMITED, APPLICATION NO. 2006200809, UNDER INID (71) CORRECT THE NAME TO READ ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY AND INDUSTRIAL RESEARCH LIMITED |
|
TC | Change of applicant's name (sec. 104) |
Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI Free format text: FORMER NAME: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY; INDUSTRIAL RESEARCH LIMITED |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |